Capsule Summary Slidesets

Share

Program Content

Activities

  • DESTINY-Breast04
    DESTINY-Breast04: Trastuzumab Deruxtecan vs Physician’s Choice of Chemotherapy for Previously Treated HER2-Low Advanced Breast Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 08, 2022

    Expires: June 07, 2023

  • TROPiCS-02
    TROPiCS-02: Phase III Trial of Sacituzumab Govitecan vs Physician’s Choice Treatment for HR+/HER2- Advanced Breast Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 08, 2022

    Expires: June 07, 2023

  • innovaTV 205
    ENGOT Cx8/GOG 3024/innovaTV 205: Interim Phase II Results With Tisotumab Vedotin Combinations in Recurrent or Metastatic Cervical Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2022

    Expires: June 08, 2023

  • FAKTION Update
    FAKTION: Updated and Expanded Analysis of Fulvestrant + Capivasertib or Placebo After Aromatase Inhibitor Therapy in ER+/HER2- Advanced Breast Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2022

    Expires: June 08, 2023

  • KEYNOTE-826: Subgroup Analysis
    KEYNOTE-826: Subgroup Analysis of Pembrolizumab + Chemotherapy ± Bevacizumab in Persistent, Recurrent, or Metastatic Cervical Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2022

    Expires: June 08, 2023

  • MAINTAIN
    MAINTAIN: Phase II Study of Switching ET ± Ribociclib for HR+/HER2- Metastatic Breast Cancer After Failure of Previous ET + CDK4/6i
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2022

    Expires: June 08, 2023

  • GARNET: Dostarlimab in EC
    GARNET: Update From Phase I Trial of Dostarlimab in Patients With Advanced or Recurrent dMMR/MSI-H or pMMR/MSS Endometrial Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 10, 2022

    Expires: June 09, 2023

  • PALOMA-2: Final OS
    PALOMA-2 Final OS Analysis: Addition of Palbociclib to Frontline Letrozole in Postmenopausal ER+/HER2- Advanced Breast Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 10, 2022

    Expires: June 09, 2023

  • ORZORA OS Results
    ORZORA: OS Results With Maintenance Olaparib in Platinum-Sensitive Relapsed Ovarian Cancer With a BRCA Mutation or Other HRR Mutation
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 13, 2022

    Expires: June 12, 2023

  • KEYNOTE-522: EFS by RCB
    KEYNOTE-522: Exploratory Analysis of EFS by Residual Cancer Burden With Neoadjuvant Pembrolizumab + Chemotherapy for Early TNBC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 14, 2022

    Expires: June 13, 2023

  • ATHENA-MONO
    ATHENA-MONO: Phase III Trial of Maintenance Rucaparib vs Placebo After First-line Platinum-Based Chemotherapy in Advanced Ovarian Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 14, 2022

    Expires: June 13, 2023

  • LUMINA
    LUMINA: Local Recurrence With Omission of Radiotherapy After Breast-Conserving Surgery in T1N0 Luminal A Breast Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 15, 2022

    Expires: June 14, 2023

  • Relacorilant in PROC
    Relacorilant, a Selective Glucocorticoid Receptor Modulator, Plus Nab-Paclitaxel in Recurrent Platinum-Resistant Ovarian Cancer: OS Analysis From a Randomized Phase II Trial
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 15, 2022

    Expires: June 14, 2023

  • MITO23
    MITO23: Phase III Trial of Trabectedin vs Investigator’s Choice of Chemotherapy for Recurrent Ovarian Cancer With BRCA Mutation or BRCAness Phenotype
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 17, 2022

    Expires: June 16, 2023

Provided by

ProCE Banner

Supporters

AbbVie

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen and Genmab